source
- FDA oncology panel votes against AstraZeneca's camizestrant trial, citing lack of meaningful benefitThe FDA's oncology advisory committee convened for the first time in about nine months and evaluated AstraZeneca's late-stage trial of its oral selective estrogen receptor degrader, camizestrant.…
- Supreme Court hints at ruling in case over generics' use of skinny-label drugsSupreme Court justices have offered preliminary signals about how they may decide a contentious lawsuit that could reshape the way generic drug makers market products with "skinny labels". The cas…